Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence - PubMed (original) (raw)
. 1980 Feb 1;243(5):446-9.
- PMID: 7351765
Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence
B L Riggs et al. JAMA. 1980.
Abstract
Thirty-six patients with primary osteoporosis were treated for up to six years with sodium fluoride, calcium supplements, and, in 24 patients, vitamin D. Major adverse reactions (synovitis, painful plantar fascial syndrome, recurrent vomiting, or anemia) occurred in 15 patients (42%). New vertebral fractures occurred at a rate of 329 fractures per 1,000 years of observation. Almost half of them occurred during the first year of therapy, and they were only one sixth as frequent in 12 patients who had fluoride-induced increased trabeculation on vertebral roentogenograms. Nevertheless, until long-term safety and antifracture efficacy are better established, this regimen should continue to be restricted to investigational use.
Similar articles
- Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.
Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Riggs BL, et al. N Engl J Med. 1982 Feb 25;306(8):446-50. doi: 10.1056/NEJM198202253060802. N Engl J Med. 1982. PMID: 6276746 Clinical Trial. - Sodium fluoride for osteoporosis--some unanswered questions.
Balink DJ, Ivey JL. Balink DJ, et al. JAMA. 1980 Feb 1;243(5):463-4. doi: 10.1001/jama.243.5.463. JAMA. 1980. PMID: 7351767 No abstract available. - Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.
Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Pak CY, et al. J Clin Endocrinol Metab. 1989 Jan;68(1):150-9. doi: 10.1210/jcem-68-1-150. J Clin Endocrinol Metab. 1989. PMID: 2909549 Clinical Trial. - The treatment of osteoporosis.
Melick RA. Melick RA. Med J Aust. 1986 Jun 9;144(12):645-7. Med J Aust. 1986. PMID: 3520261 Review. No abstract available.
Cited by
- Lack of any estrogenic effect of ipriflavone in postmenopausal women.
Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P. Melis GB, et al. J Endocrinol Invest. 1992 Nov;15(10):755-61. doi: 10.1007/BF03347647. J Endocrinol Invest. 1992. PMID: 1491124 Clinical Trial. - Gastroduodenal manifestations in patients with skeletal fluorosis.
Dasarathy S, Das TK, Gupta IP, Susheela AK, Tandon RK. Dasarathy S, et al. J Gastroenterol. 1996 Jun;31(3):333-7. doi: 10.1007/BF02355021. J Gastroenterol. 1996. PMID: 8726823 - Transforming activities of sodium fluoride in cultured Syrian hamster embryo and BALB/3T3 cells.
Lasne C, Lu YP, Chouroulinkov I. Lasne C, et al. Cell Biol Toxicol. 1988 Sep;4(3):311-24. doi: 10.1007/BF00058739. Cell Biol Toxicol. 1988. PMID: 3224306 - Effects of cortisol and fluoride on ion-transporting ATPase activities in cultured osteoblastlike cells.
Anderson RE, Kemp JW, Jee WS, Woodbury DM. Anderson RE, et al. In Vitro. 1984 Nov;20(11):847-55. doi: 10.1007/BF02619630. In Vitro. 1984. PMID: 6097529 - Substituted hydroxyapatites for bone repair.
Shepherd JH, Shepherd DV, Best SM. Shepherd JH, et al. J Mater Sci Mater Med. 2012 Oct;23(10):2335-47. doi: 10.1007/s10856-012-4598-2. Epub 2012 Mar 3. J Mater Sci Mater Med. 2012. PMID: 22389101
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical